Strs Ohio Sells 20,700 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Strs Ohio lowered its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 20.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 81,300 shares of the company’s stock after selling 20,700 shares during the quarter. Strs Ohio’s holdings in Hims & Hers Health were worth $723,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. FNY Investment Advisers LLC bought a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $48,000. Belpointe Asset Management LLC bought a new position in shares of Hims & Hers Health during the 3rd quarter worth approximately $76,000. EMC Capital Management lifted its position in shares of Hims & Hers Health by 80.0% during the 3rd quarter. EMC Capital Management now owns 12,000 shares of the company’s stock worth $79,000 after buying an additional 5,332 shares during the period. Corton Capital Inc. bought a new position in shares of Hims & Hers Health during the 3rd quarter worth approximately $122,000. Finally, Custom Index Systems LLC bought a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $132,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $12.27 on Friday. The stock has a fifty day moving average of $13.70 and a 200-day moving average of $10.01. The stock has a market capitalization of $2.63 billion, a P/E ratio of -111.50 and a beta of 0.91. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $17.16.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 26th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.03. The company had revenue of $246.60 million during the quarter, compared to analysts’ expectations of $245.84 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The business’s revenue for the quarter was up 47.4% on a year-over-year basis. During the same period last year, the firm earned ($0.05) EPS. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on HIMS shares. Jefferies Financial Group restated a “hold” rating and set a $15.00 target price (down previously from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Leerink Partnrs restated a “market perform” rating on shares of Hims & Hers Health in a research report on Monday, February 26th. TheStreet raised Hims & Hers Health from a “d” rating to a “c” rating in a report on Monday, March 4th. Canaccord Genuity Group started coverage on Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target for the company. Finally, Tigress Financial raised their price target on Hims & Hers Health from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday, January 5th. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health has a consensus rating of “Moderate Buy” and an average target price of $14.85.

Insider Buying and Selling

In related news, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction on Monday, April 1st. The stock was sold at an average price of $15.65, for a total transaction of $39,171.95. Following the completion of the sale, the insider now directly owns 166,866 shares of the company’s stock, valued at $2,611,452.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction on Monday, April 1st. The stock was sold at an average price of $15.65, for a total transaction of $39,171.95. Following the completion of the sale, the insider now directly owns 166,866 shares of the company’s stock, valued at $2,611,452.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $14.97, for a total value of $2,827,653.36. The disclosure for this sale can be found here. Insiders sold a total of 548,150 shares of company stock valued at $7,327,717 over the last three months. Company insiders own 31.63% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.